Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2023-11-24 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Agreement' involving the company's largest shareholder. It provides specific details on collateralized shares, loan amounts, and contract terms. This type of disclosure regarding financing and capital structure changes falls under the 'Capital/Financing Update' category.
2023-11-24 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Stock Collateral Provision Agreement' (주식 담보제공 계약). It details changes to collateral terms, loan extensions, and lists specific financial institutions involved. This type of disclosure regarding financing arrangements and collateralization of shares by a major shareholder is classified under 'Capital/Financing Update' (CAP) as it pertains to the company's capital structure and financing activities.
2023-11-14 Korean
[기재정정]반기보고서 (2023.06)
Interim / Quarterly Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Semi-Annual Report' (반기보고서). It details specific corrections made to the company's business purpose and shareholder information. In the context of financial filings, a correction to a previously submitted interim/quarterly report is classified under the same category as the report itself, which is an Interim/Quarterly Report (IR). H1 2023
2023-11-14 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for GemVax & KAEL Co., Ltd. covering the period from January 1, 2023, to September 30, 2023. It contains detailed company information, business descriptions, financial data, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for directors and major shareholders to disclose their personal share transactions (insider trading). Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2023-11-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings, and contractual relationships (such as pledges and loans) of a major shareholder (Gem & Company) and its special related parties in the company GemVax & KAEL. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-11-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.